MET and glioblastoma: PTEN status affected anti-c-MET therapies to glioblastomas in which PTEN protein expression was frequently low or absent, and combining anti-HGF/c-MET therapies with mTOR inhibitors additively inhibited growth of glioblastoma xenografts [46].